10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sasanlimab)

Recombinant Antibody Catalog # APR10391

Product Information

Application FC, Kinetics, Animal Model

Primary Accession

Reactivity

Clonality

Isotype

Calculated MW

Q15116

Human

Monoclonal

IgG4SP

31647

Additional Information

Target/Specificity PDCD1 / PD-1 / CD279

Endotoxin

Conjugation Unconjugated

Expression system CHO Cell

Format Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

Protein Information

Name PDCD1 {ECO:0000303 | PubMed:7851902, ECO:0000312 | HGNC:HGNC:8760}


Function Inhibitory receptor on antigen activated T-cells that plays a critical role in

induction and maintenance of immune tolerance to self (PubMed:<u>21276005</u>, PubMed:<u>37208329</u>). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:<u>21276005</u>). Following T-cell


receptor (TCR) engagement, PDCD1 associates with CD3- TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).

Cellular Location Cell membrane; Single-pass type I membrane protein

Images



Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sasanlimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sasanlimab)is more than 95% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.